Michael M. Wick
11Patents
7h-index
16Co-inventors
59Inventor score
Filing activity: Jul 1, 1994 → Oct 15, 2007
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5866702A | Purine inhibitors of cyclin dependent kinase 2 | Chemistry; Metallurgy | 102 | Expired |
| US5789416A | N.sup.6 mono heterocyclic substituted adenosine derivatives | Human Necessities | 57 | Expired |
| US6075150A | .alpha.-ketoamide inhibitors of 20S proteasome | Human Necessities | 55 | Expired |
| US6781000B1 | Alpha-ketoamide inhibitors of 20S proteasome | Human Necessities | 40 | Expired |
| US6794390B2 | Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha | Chemistry; Metallurgy | 31 | Expired |
| US5834487A | Inhibition of 26S and 20S proteasome by indanones | Chemistry; Metallurgy | 17 | Expired |
| US6790958B2 | Purine inhibitors of cyclin dependent kinase 2 & IKBA | Physics | 7 | Expired |
| US7109330B2 | Purine inhibitors of cyclin dependent kinase 2 and IκB-α | Physics | 4 | Expired |
| US5593671A | Method of attenuating lung capillary leak in a mammal | Human Necessities | 4 | Expired |
| US6117887A | Inhibition of 26S and 20S proteasome by indanones | Chemistry; Metallurgy | 3 | Expired |
| US8207121B2 | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.